For tattoo Removal
L.A.
New laser-based medical device Patent
Provectus to Receive Fifth Medical Device
Patent
Will Expand Portfolio of Technologies Available for
Out-Licensing
Thursday December 22, 7:30 am ET
Press Release Source: Provectus Pharmaceuticals, Inc.
KNOXVILLE, Tenn., Dec. 22 /PRNewswire-FirstCall/ --
Provectus Pharmaceuticals, Inc. (OTC Bulletin Board: PVCT - News)
announced today that it has received a notice of allowance for a patent
application covering the Company's laser-based technologies for selective
destruction of pigmented tissue, with applicability to elimination of moles and
pigmented skin cancers, such as melanomas. The notice of allowance from the U.S.
Patent and Trademark Office indicates that the application is in condition for
issuance and a U.S. patent will be issued within several months. The patent is
anticipated to be the Company's sixteenth U.S. patent and the fifth patent for
its medical device technologies.
The pending patent covers methods for use of advanced laser technologies in the
destruction of pigmented tissue. Additional areas of applicability include
selective destruction of hair follicles for hair reduction
along with tattoo removal.
"These methods are fundamental to a range of new laser-based medical devices
that should dramatically improve the selectivity and effectiveness of treatments
for important skin conditions, both in the therapeutic and cosmetic arenas,"
said Craig Dees, Ph.D., Provectus CEO and co-inventor. "We continue to assemble
an attractive portfolio of technologies that are available for licensure to the
medical device industry."
Provectus' laser technologies harness the energy of pulsed lasers in a precise
manner that minimizes damage to tissue surrounding the targeted treatment area.
In addition, these technologies enable the selective destruction of target
tissues based on their inherent light absorption.
About Provectus Pharmaceuticals, Inc.
Provectus Pharmaceuticals, Inc. is a pioneering pharmaceutical company actively
engaged in the design, development, and marketing of pharmaceutical technologies
for the treatment of metastatic melanoma, breast cancer and liver cancer. In
addition, Provectus is preparing to begin Phase 2 clinical studies for the
Company's topical agent Xantryl(TM), a treatment for psoriasis.
The Company's offices and laboratory are located at 7327 Oak Ridge Highway,
Suite A, Knoxville, TN 37931; telephone: 865 769 4011.
For more information, contact the Company at info@pvct.com or visit the
corporate Web site: http://www.pvct.com.
This release and others statements issued or made from time to
time by the company or its representatives contain comments that may constitute
forward- looking statements. Those include statements regarding the intent,
belief or current expectations of the company and members of its management
teams, as well as the assumptions on which the statements are based. Prospective
investors are cautioned that such forward-looking statements are not guarantees
of future performance and involve risks and uncertainties, and that actual
results may differ materially from those contemplated by such forward- looking
statements.
To visit this
Article's source online go to:
http://biz.yahoo.com/prnews/051222/nyth020.html?.v=34
